Anteris Technologies Global Corp. has announced plans for a $200 million underwritten public offering of common stock, with the potential for an additional $30 million in shares through a 30-day option granted to underwriters.

The offering, which is subject to market conditions, is accompanied by a separate private placement agreement with Medtronic. Under the agreement, Medtronic will acquire up to $90 million in Anteris common stock, representing between 16% and 19.99% of shares outstanding following the offering. The private placement is contingent on the completion of the public offering, but the reverse is not required.

Based in Brisbane, Australia, with operations in Minneapolis, Anteris plans to use proceeds from both the public and private offerings to support clinical and operational growth. Funding will go toward the ongoing PARADIGM trial, a global pivotal study evaluating the company’s DurAVR transcatheter heart valve in patients with severe aortic stenosis. Additional capital will be used to scale manufacturing, support R&D efforts, including for subsidiary v2vmedtech, and for general corporate purposes.
DurAVR is a balloon-expandable valve made from Anteris’ ADAPT tissue technology, which is designed to resist calcification. The company says the valve aims to replicate natural blood flow dynamics through biomimetic design. The device is currently being studied in a multicenter clinical trial (NCT07194265), with initial patient implants completed in Denmark in late 2025.

Barclays, Wells Fargo Securities and Cantor are acting as joint book-running managers for the offering, while Wells Fargo Securities is also serving as the sole placement agent for the Medtronic investment. Barrenjoey Markets is advising on the offering in Asia-Pacific and select markets outside the U.S. and Canada.

Shares offered in the public sale are being made under an effective shelf registration filed with the SEC earlier this month. The Medtronic investment will be made under a private placement exemption

Cardiology Homepage